AMGA Health Services Research Opportunities
By its nature, implementation science fosters innovations that originate at the clinic level in response to real-world challenges. AMGA Analytics’ studies combine quantitative data (Optum® data assets) with qualitative data collected from AMGA member organizations.
AMGA works with members, AMGA Corporate Partners, and distinguished national research partners to tackle major challenges healthcare organizations are facing today. Below are current research projects that have implications for AMGA member organizations. Please let us know if your organization has an interest in participating in research related to these projects.
Current Research Opportunities
Evaluation of the Implementation of an At-Home Urinalysis Kit (Currently recruiting):
This implementation study evaluates the use of Healthy.io’s proprietary home-based Smartphone Urinalysis Kit in an at-risk population. [Read More]
Chronic Pain Management and Opioid Prescribing (Currently recruiting):
Evaluates the impact of clinical practice guidelines and health system policies on chronic pain management, opioid prescribing, opioid use disorder, and medications to treat opioid use disorder (MOUD) in medical groups and health systems.
Piloting Predictive Models Within the Clinical Workflow
- Enhanced Decision Making for Patients with Prediabetes: This predictive model uses data available in the electronic health record (EHR) to estimate individualized treatment benefits of taking metformin or participating in the Diabetes Prevention Program. [Read More]
With funding from the Patient-Centered Outcomes Research Institute (PCORI), AMGA is working with Mercy (Midwest) and Premier Medical Associates (Pennsylvania) to apply a model created at Tuft’s Predictive Analytics and Comparative Effectiveness (PACE) Center. With its emphasis on shared decision-making, the model is already making a difference. At Mercy, the model is being implemented via a cloud-hosted SMART app using FHIR resources. This EHR interoperability technology will allow provider organizations to embed sophisticated predictive models in the clinical workflow within any leading EHR, enabling rapid scalability to other AMGA members. Sign up for information about this and other research opportunities at AMGA HSR Partner.
- Chronic Kidney Disease Patch for ASCVD Risk Calculator: This project will enhance the current AHA/ACC ASCVD risk calculator by integrating kidney function data into the risk calculation for more precise risk prediction. [Read More]
AMGA Analytics, has received funding for practical implementation of a novel chronic kidney disease (CKD) patch for the AHA/ACC ASCVD risk calculator, developed in partnership with the Chronic Kidney Disease Prognosis Consortium (CKD-PC) at Johns Hopkins University (JHU). By integrating kidney data into risk estimation, the patch improves ASCVD risk estimates overall, and results in meaningful ASCVD risk reclassification, particularly among higher-risk CKD. The patch will be applied via a SMART app using FHIR resources for smoother user interface in the EHR. AMGA has partnered with Interopion for the development of the SMART Application and EHR integration, making risk estimates available for shared decision making, at the point of care, and expand use into practice and the clinical workflow. One AMGA integrated health system will implement and pilot test with providers and patients. Sign up for information about this and other research opportunities at AMGA HSR Partner.
Supporting Transformation to a Value-Based Healthcare System:
Supports work on field-based, real-world informed development, testing, and implementation of new approaches for improving care based on program priorities determined by the Agency for Health Research and Quality (AHRQ). [Read More]
Managing Transitions and Anticoagulation for Patients with venous thromboembolism VTE after hospital discharge (Currently recruiting):
AMGA is looking for physicians who treat patients with VTE [includes pulmonary embolism (PE) and/or deep vein thrombosis (DVT)] in the hospital or ambulatory setting. AMGA will conduct a focus group and follow-up with interviews to help us understand how hospitalized patients with PE and/or DVT are being transitioned after discharge when longer-term anticoagulation is indicated. [Read More]
Last summer, the European Society for Cardiology (ESC) updated the ESC Guidelines for Acute Pulmonary Embolism that include strong recommendations for extension of oral anticoagulant treatment for patients with recurrent VTE not related to a major transient or reversible risk factor and for patients with a first episode of pulmonary embolism (PE) with no identifiable risk factor. A small number of AMGA members will be recruited to participate in the study that seeks to identify barriers that hinder implementation of the ESC guidelines into practice. Sign up for information about this and other research opportunities at AMGA HSR Partner.
In the U.S., 10% of patients with acute VTE are readmitted with a recurrence within 30 days.1 One study showed the mean cost for a hospital admission with a principal diagnosis of VTE is $19,000 and for readmissions with principal diagnoses of DVT and PE, costs are $15,000 and $23,000, respectively.2 AMGA believes there may be opportunities to improve transitions of care from the hospital and management of VTE in ambulatory settings.
- Secemsky EA, Rosenfield K, Kennedy KF, Jaff M, Yeh RW. High Burden of 30-Day Readmissions After Acute Venous Thromboembolism in the United States. J Am Heart Assoc. 2018;7(13):e009047. Published 2018 Jun 26. doi:10.1161/JAHA.118.009047
- Amin A, Deitelzweig S, Bucior I, et al. Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US. J Med Econ. 2019;22(11):1119-1125. doi:10.1080/13696998.2019.1618862
Research Opportunities in the Pipeline
Implementation Research Initiative (IRI) for the Improvement of Care for Patients with Osteoarthritis:
The purpose of this initiative is to improve identification and management of patients with osteoarthritis (OA) through an implementation project with up to 10 AMGA members. [Read More]